Sequencing the first human genome took 13 years and cost $3 billion. Now, you can sequence a genome in a day for $200. That's the power of next‑generation sequencing (NGS). The life science & analytical instruments market research shows that NGS is the fastest‑growing technology segment, with a CAGR above 12%. Why? Because it's enabling personalised medicine, liquid biopsies, and infectious disease surveillance.

What's driving adoption? Research applications are the fastest‑growing end‑use segment, as academic labs and biotech companies use NGS for everything from CRISPR validation to single‑cell transcriptomics. The life science & analytical instruments market trends highlight that the fastest‑growing application is clinical diagnostics, as NGS is now used for cancer panels, rare disease diagnosis, and even prenatal testing (NIPT).

But NGS has challenges: data storage and analysis. A single human genome generates 200 GB of raw data. That's why cloud computing and AI are essential partners. Also, reimbursement is still spotty for many NGS tests, limiting access.

The takeaway: NGS is democratising genomics, but it's not magic. It requires skilled bioinformaticians and robust quality control. If you're a researcher, learn to analyse NGS data — it's a career‑boosting skill.